Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program

M. Prisciandaro, R. Ratta, F. Massari, G. Fornarini, S. Caponnetto, R. Iacovelli, U. De Giorgi, G. Facchini, S. Scagliarini, R. Sabbatini, C. Caserta, G. Peverelli, A. Mennitto, E. Verzoni, G. Procopio

Research output: Contribution to journalArticle

Cite this

Prisciandaro, M., Ratta, R., Massari, F., Fornarini, G., Caponnetto, S., Iacovelli, R., De Giorgi, U., Facchini, G., Scagliarini, S., Sabbatini, R., Caserta, C., Peverelli, G., Mennitto, A., Verzoni, E., & Procopio, G. (2019). Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program. American Journal of Clinical Oncology: Cancer Clinical Trials, 42(1), 42-45. https://doi.org/10.1097/COC.0000000000000478